Bimodal Neuromodulation for Tinnitus: What the Evidence Shows
The short answer
Bimodal neuromodulation pairs sound with electrical stimulation (tongue or skin) to target the brain circuits behind tinnitus. Two device programs lead the field: Lenire (FDA De Novo authorized, available now) and the Shore/Auricle device (positive academic trial, awaiting FDA review). Trials report meaningful distress improvements; independent replication is still missing for both, and neither is established to make tinnitus quieter for the typical patient.
Lenire
Pairs sound with mild tongue stimulation — the first and only device of its type the FDA has authorized for tinnitus. Large trials and real-world data, but all company-funded and none with a placebo group.
Replication: Same group/sponsor only. Independence: Primarily sponsor-supported. Every efficacy trial to date was funded and run by Neuromod Devices; a key author is Neuromod's CSO.
Shore / Auricle bisensory device
The only treatment with rigorous randomized evidence of making tinnitus quieter — still stuck in the lab.
Replication: Same group/sponsor only. Independence: Mixed. Trials were NIH-funded, but run by the device inventors, who co-founded the company commercializing it (Auricle).
How to think about the difference
Lenire's evidence is larger but entirely sponsor-run; the Shore trials are NIH-funded but inventor-led and used a psychoacoustic loudness co-primary that missed statistical significance in the main analysis at week 6. Both are honest reasons for caution, not dismissal. See each page's limitations and study records for the full picture.